Recruiting
Phase 2
Phase 3

taVNS

Sponsor:

Medical University of South Carolina

Code:

NCT07049952

Conditions

Feeding Delays

Neonates and Term Infants

Eligibility Criteria

Sex: All

Age: 0 - 1

Healthy Volunteers: Not accepted

Interventions

taVNS

NAC and taVNS

inactive taVNS

sterile water and inactive taVNS

Study Details

Brief summary:

The long-term goal of this project is to develop a therapy to assist pre-term and term infants with brain injury overcome difficulties in learning to feed so that infants may be discharged home with their families and avoid the burdens of of a gastrostomy tube (G-tube) or prolonged home nasogastric feeding. Few other therapies exist for infants who are not making progress with feeding volumes at term age.

To tackle this problem, we took the novel approach of pairing non-invasive nerve stimulation of the vagus nerve at the ear (taVNS) stimulation with the motor skills of feeding. In our pilot studies, 54% (19 out of 35) infants with feeding delays whose families were in discussions for G-tube placement, reached full oral feeds within 2 weeks, and infants who did not reach full feeds still improved their daily oral feeding volumes. Infants who got to full feeds showed stronger and more complex brain circuits associated with feeding motor skills.

With this trial we will test the BabySTrong taVNS feeding system in a multicenter, randomized, controlled, blinded trial to show how well this feeding system works in improving the daily feeding volumes, the days to full oral feeds, and/or the number of infants who avoid G-tube/ home NG placement, and increasing connections in brain circuits. If this groundbreaking new approach to infant feeding is successful, we may decrease how long infants are in the hospital, costs with Gtubes and home NG feeds, and family and care provider burdens. The findings from this proposal will be used in our FDA application for the BabySTrong feeding system.

Conditions

Feeding Delays

Neonates and Term Infants

Study ID

NCT07049952

Start date

Nov 16, 2025

Status verified date

Nov, 2025

Completion date

Dec 30, 2027

Anticipated

Primary completion date

Apr 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 1

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • infants >39 weeks PMA making minimal progress in oral feeds
  • trying to learn feeding for at least 2wks if beginning feeds at term (>37wks PMA), and 4wks if beginning feeds <36wks PMA,
  • may po every feed without volume limitations by therapists

Exclusion Criteria:

  • cardiomyopathy
  • unstable apnea/bradycardia
  • significant respiratory support (CPAP/ Vapotherm)
  • unrepaired major congenital anomalies that affect safe po feeding or impose volume restrictions
  • congenital syndromes unlikely to orally feed

Study Design

Enrollment

88 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Non-IDM active taVNS

Non-IDM (Infants not product of diabetic mothers) will receive active taVNS with 2 feeds/day x 14 days

sham comparator: Non-IDM Control

Non-IDM (Infants not product of diabetic mothers) will receive inactive/sham taVNS paired with 2 oral feedings a day for 14 days.

active comparator: IDM NAC and active taVNS

Infants of diabetic mothers will receive N-acetylcysteine by NG tube every 6h and active taVNS paired with 2 oral feedings a day, as a drug and device combination treatment for 14 days.

sham comparator: IDM Control

Infants of diabetic mothers will receive sterile water and inactive taVNS paired with 2 oral feedings a day, as a placebo drug and sham device combination treatment, for 14 days.

Interventions

taVNS

Active or inactive non-invasive vagus nerve stimulation of the auricular branch of the vagus nerve paired with 2 oral feedings/day for 14d

NAC and taVNS

NAC 100 mg/kg diluted 1:3 with sterile water (or equal volume sterile water), q6h NG 1h before a feed for 4d prior to delivering active or sham taVNS paired with 2 feeds/day for 14d with NAC (or sterile water).

inactive taVNS

inactive transcutaneous auricular vagus nerve stimulation with 2 feeds/day x 14 days

sterile water and inactive taVNS

Sterile water per NG tube every 6h for 4 days, then continuing with 14days of inactive taVNS paired with oral feeding

Primary outcome measure

  • number of participants at full oral feeds [ Time Frame: 24 days ]
  • rate of increase in daily oral feeding volumes [ Time Frame: 7days / 10days ]

Central Contacts and Locations

Central contacts

Locations

Shawn Jenkins Children's Hospital, Medical University of South Carolina

Recruiting

Charleston, South Carolina, United States, 29425

Contacts

Dorothea D Jenkins, MD

843-792-2112jenkd@musc.edu

More Information

Sponsor

Medical University of South Carolina

Last update posted

Nov 21, 2025

Last verified

Nov, 2025

Keywords

  • taVNS
  • feeding delays
  • infants
  • IDM
  • non-IDM
  • G-tube
  • transcutaneous auricular vagus nerve stimulation
  • Home NG feeds

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Medical University of South Carolina on 2025-11-21.